Clinical trial
An Extension Study to Determine the Efficacy and Safety of STI571 in…
NCT00171223 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171223 |
|---|---|
| Title | An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha |
| Official title | An Extension to a Phase II Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| Intervention type | Drug |
| Interventions | STI571 |
| Enrollment | 532 |
| Start date | Dec 6, 1999 |
| Primary completion | Nov 29, 2013 |
| Completion | Nov 29, 2013 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 22, 2021 |
| Countries | France, Germany, Italy, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: